WO2011018185A3 - Pharmaceutical tablet comprising rosuvastatin calcium - Google Patents

Pharmaceutical tablet comprising rosuvastatin calcium Download PDF

Info

Publication number
WO2011018185A3
WO2011018185A3 PCT/EP2010/004796 EP2010004796W WO2011018185A3 WO 2011018185 A3 WO2011018185 A3 WO 2011018185A3 EP 2010004796 W EP2010004796 W EP 2010004796W WO 2011018185 A3 WO2011018185 A3 WO 2011018185A3
Authority
WO
WIPO (PCT)
Prior art keywords
rosuvastatin calcium
pharmaceutical tablet
tablet
core
polyvinylalcohol
Prior art date
Application number
PCT/EP2010/004796
Other languages
French (fr)
Other versions
WO2011018185A2 (en
Inventor
Marta Vivancos
Original Assignee
Synthon B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon B.V. filed Critical Synthon B.V.
Priority to EA201270269A priority Critical patent/EA201270269A1/en
Priority to AU2010281913A priority patent/AU2010281913A1/en
Priority to EP10739873A priority patent/EP2464344A2/en
Publication of WO2011018185A2 publication Critical patent/WO2011018185A2/en
Publication of WO2011018185A3 publication Critical patent/WO2011018185A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a tablet comprising: i) a compressed core, which comprises rosuvastatin calcium, a dibasic calcium phosphate, and at least one pharmaceutically acceptable excipient; and ii) moisture barrier layer around said core, which comprises a polyvinylalcohol, to a process for making the tablet and use in medicine.
PCT/EP2010/004796 2009-08-13 2010-07-29 Pharmaceutical tablet comprising rosuvastatin calcium WO2011018185A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EA201270269A EA201270269A1 (en) 2009-08-13 2010-07-29 PHARMACEUTICAL TABLET CONTAINING ROSUVASTATIN CALCIUM
AU2010281913A AU2010281913A1 (en) 2009-08-13 2010-07-29 Pharmaceutical tablet comprising rosuvastatin calcium
EP10739873A EP2464344A2 (en) 2009-08-13 2010-07-29 Pharmaceutical tablet comprising rosuvastatin calcium

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23354209P 2009-08-13 2009-08-13
US61/233,542 2009-08-13

Publications (2)

Publication Number Publication Date
WO2011018185A2 WO2011018185A2 (en) 2011-02-17
WO2011018185A3 true WO2011018185A3 (en) 2011-11-24

Family

ID=43334705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/004796 WO2011018185A2 (en) 2009-08-13 2010-07-29 Pharmaceutical tablet comprising rosuvastatin calcium

Country Status (4)

Country Link
EP (1) EP2464344A2 (en)
AU (1) AU2010281913A1 (en)
EA (1) EA201270269A1 (en)
WO (1) WO2011018185A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO129060B1 (en) 2013-04-25 2014-11-28 Antibiotice S.A. Stable pharmaceutical composition with amorphous rosuvastatin calcium
CN104473899B (en) * 2014-12-19 2017-10-03 河南润弘制药股份有限公司 A kind of rosuvastatin calcium tablets agent and preparation method thereof
BR112019009709A2 (en) * 2016-11-15 2019-08-13 Lg Chemical Ltd combination preparation.
GB2622822A (en) 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185102A1 (en) * 2002-12-20 2004-09-23 Pfizer Inc Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
WO2006079611A1 (en) * 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (en) 1991-07-01 1997-09-03 塩野義製薬株式会社 Pyrimidine derivatives
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
WO2008075320A2 (en) * 2006-12-21 2008-06-26 Ranbaxy Laboratories Limited Antilipidemic pharmaceutical compositions and process for preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040185102A1 (en) * 2002-12-20 2004-09-23 Pfizer Inc Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
WO2006079611A1 (en) * 2005-01-31 2006-08-03 Ciba Specialty Chemicals Holding Inc. Crystalline forms of rosuvastatin calcium salt

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2464344A2 *

Also Published As

Publication number Publication date
EP2464344A2 (en) 2012-06-20
EA201270269A1 (en) 2012-09-28
AU2010281913A1 (en) 2012-04-05
WO2011018185A2 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
IL216522A (en) Tamper-resistant pharmaceutical dosage form, packaging comprising the same and process for its production
WO2008146178A3 (en) A novel tablet dosage form
MX2010004323A (en) Oral dosage forms comprising licarbazîžpine acetate.
NZ605352A (en) Process for producing glycosaminoglycans
WO2010146179A3 (en) Solid pharmaceutical composition comprising rivaroxaban
JO3757B1 (en) Pharmaceutical compositions comprising nilotinib or its salt
WO2012131463A3 (en) Controlled release pharmaceutical dosage forms
HUE037742T2 (en) Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof
WO2009047321A3 (en) A sublingual effervescent tablet of progesterone associated with cyclodextrin
WO2010097243A3 (en) Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts
CA2863376A1 (en) Gastroretentive tablets
WO2010012459A3 (en) A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms
EP2292242A4 (en) A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof
WO2011018185A3 (en) Pharmaceutical tablet comprising rosuvastatin calcium
WO2009149058A3 (en) Modified release niacin formulations
GB2455875B (en) A process for the preparation of an orally administered unit dose tablet
WO2011155728A3 (en) Composition for preventing or treating osteoporosis, and manufacturing method therefor
WO2012085249A3 (en) Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
WO2010081722A3 (en) Orally disintegrating tablets for the treatment of pain
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
GB0703674D0 (en) A Process For The Preparation of an Orally Administered Unit Dose Tablet
EP2292241A4 (en) A scutellarin derivative, the preparing process, the pharmaceutical composition and the use thereof
WO2008046538A3 (en) Non-steroid antiphlogistics against coughing
MX2014010038A (en) Taste masked dispersible tablets.
WO2011018246A3 (en) Controlled release paliperidone composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10739873

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010739873

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010281913

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: A201202922

Country of ref document: UA

Ref document number: 201270269

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2010281913

Country of ref document: AU

Date of ref document: 20100729

Kind code of ref document: A